Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083 28/03/2023

0,710 USD (-7,80%)

(-7,80%) 28/03/2023

Grafiek Nektar Therapeutics

Grafiek Nektar Therapeutics

1 dag1d -7,80%
1 week1w -9,90%
1 maand1m -48,52%
3 maanden3m -67,71%
6 maanden6m -76,63%
1 jaar1j -87,65%
5 jaar5j -99,33%

Nektar Therapeutics in het nieuws

Toon enkel gratis nieuws

12 maart 2023 · Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank · Persbericht

28 februari 2023 · Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results · Persbericht

23 februari 2023 · Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus · Persbericht

4 januari 2023 · Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA · Persbericht

15 december 2022 · Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm · Persbericht

12 december 2022 · Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting · Persbericht

5 december 2022 · Nektar Therapeutics to Host Investor & Analyst Event on December 12th · Persbericht

10 november 2022 · Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting · Persbericht

9 november 2022 · Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy · Persbericht

3 november 2022 · Nektar Therapeutics Reports Third Quarter 2022 Financial Results · Persbericht

336x280

Profiel Nektar Therapeutics

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.nektar.com

Hoofdzetel: San Francisco, California Verenigde Staten

CEO: Howard Robin

Werknemers: 718

Aandelen Nektar Therapeutics

Beurswaarde: 145,81 miljoen USD

Effecten: 189,24 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,44

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe